See more : SGS SA (SGSOY) Income Statement Analysis – Financial Results
Complete financial analysis of Neoleukin Therapeutics, Inc. (NLTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neoleukin Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Ryohin Keikaku Co., Ltd. (7453.T) Income Statement Analysis – Financial Results
- Hunan Gold Corporation Limited (002155.SZ) Income Statement Analysis – Financial Results
- Iwabuchi Corporation (5983.T) Income Statement Analysis – Financial Results
- PT Paramita Bangun Sarana Tbk (PBSA.JK) Income Statement Analysis – Financial Results
- Canadian Western Bank (CWESF) Income Statement Analysis – Financial Results
Neoleukin Therapeutics, Inc. (NLTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neoleukin.com
About Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 41.13M | 39.16M | 24.34M | 4.42M | 41.79M | 36.27M | 28.38M | 15.80M | 18.08M | 7.54M | 6.05M |
| General & Administrative | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Other Expenses | -42.00K | 6.00K | -44.00K | -8.00K | -445.00K | -39.00K | -43.00K | -369.00K | -254.89K | 0.00 | 64.03K |
| Operating Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Cost & Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Interest Income | 1.58M | 19.00K | 490.00K | 1.54M | 1.56M | 998.00K | 619.00K | 0.00 | 0.00 | 26.32K | 0.00 |
| Interest Expense | 1.58M | 0.00 | 0.00 | 1.00K | 4.00K | 4.00K | 1.00K | 99.00K | 461.59K | 42.92K | 9.47K |
| Depreciation & Amortization | 2.61M | 2.28M | -13.84M | 49.59M | 1.04M | 940.00K | 644.00K | -421.00K | 135.95K | 59.57K | 130.78K |
| EBITDA | -56.49M | -60.70M | -47.56M | -21.37M | -31.51M | -50.16M | -37.07M | -21.71M | -24.38M | -9.68M | -7.53M |
| EBITDA Ratio | 0.00% | -1,011,633.33% | -10,546.34% | 0.00% | -126.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -59.10M | -60.70M | -33.73M | -70.96M | -32.62M | -51.12M | -37.65M | -21.34M | -23.57M | -9.38M | -7.66M |
| Operating Income Ratio | 0.00% | -1,011,633.33% | -7,478.49% | 0.00% | -130.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.54M | 6.00K | 7.83M | 1.52M | 1.04M | 936.00K | 643.00K | -520.00K | 487.60K | 641.24K | -9.47K |
| Income Before Tax | -57.56M | -60.69M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -24.03M | -8.73M | -7.67M |
| Income Before Tax Ratio | 0.00% | -1,011,533.33% | -7,378.49% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.54M | -2.28M | -8.32M | -7.00K | -1.04M | -940.00K | -644.00K | 421.00K | -222.00 | -5.04K | 42.29K |
| Net Income | -56.02M | -58.42M | -24.96M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -23.82M | -9.30M | -12.14M |
| Net Income Ratio | 0.00% | -973,583.33% | -5,533.48% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| EPS Diluted | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| Weighted Avg Shares Out | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
| Weighted Avg Shares Out (Dil) | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
Despite virus-related obstacles, baseball reaches postseason
Pandemic playoffs: Brewers, Astros in despite losing records; Blue Jays face Rays on Tuesday
Novo Exercises Option Over GBM Resources’ Malmsbury Gold Project
Novo Acquires Option Over Kalamazoo Resources Limited’s Queens Project
Novo Sells Part of Blue Spec Project to Calidus Resources for Cash Consideration of A$19.5 Million
Novo Nordisk A/S – Share repurchase programme
Source: https://incomestatements.info
Category: Stock Reports